


ÇELIKYÜREKLI, SIMAY, Post doc

GENERAL INFORMATION



PostDoc

Hopp Children's Cancer Center at NCT Heidelberg (KITZ)
Clinical Cooperation Unit Pediatric Oncology / German Cancer Research Center
(DKFZ)
Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
Email: s.celikyurekli@kitz-heidelberg.de

A02

ACADEMIC EDUCATION & QUALIFICATION

Year(s)	Education
2024	Dr. rer. nat, DKFZ/Faculty of Biosciences, Heidelberg University
2019	M.Sc., Molecular Biosciences/Major Infectious Diseases, Heidelberg University
2017	B.Sc., Molecular Biology and Genetics, Bilkent University

SCIENTIFIC EDUCATION & QUALIFICATION

Year(s)	Education
2024-present	PostDoc, CCU Pediatric Oncology, KITZ/DKFZ
2020-2024	Dr. rer. nat (Magne cum Laude), CCU Pediatric Oncology, KITZ/DKFZ/Faculty of Biosciences, Heidelberg University Thesis: Specific combination therapy for H3K27M pediatric diffuse midline glioma Supervisor: Dr. Ina Oehme
2019	Master Thesis, Tumorvirus-specific Vaccination Strategies, DKFZ Thesis: Generation and characterization of monoclonal antibodies targeting a cross-neutralization epitope of minor capsid protein L2 of human papillomavirus 3 and 4 Supervisor: Prof. Martin Müller

PROFESSIONAL EXPERIENCE

Year(s)	Experience
2024-present	PostDoc, CCU Pediatric Oncology, KITZ/DKFZ
2020-2024	PhD, CCU Pediatric Oncology, KITZ/DKFZ/Faculty of Biosciences, Heidelberg University
2019	Master thesis student, Tumorvirus-specific Vaccination Strategies, DKFZ, Heidelberg, Germany Supervisor: Prof. Martin Müller
2018	Intern, BioQuant, Cluster of Excellence CellNetworks, Heidelberg, Germany Supervisor: Prof. Dirk Grimm
2018	Intern, Heidelberg University Medical Faculty Department of Infectious Diseases, Parasitology, Heidelberg, Germany Supervisor: Prof. Michael Lanzer
2015-2017	Research fellow, Synthetic Biosystems and Bionanotechnology Laboratory, National Nanotechnology and Research Center (UNAM), Bilkent University, Ankara, Turkey Supervisor: Assoc. Prof. Urartu Özgür Şafak Şeker
2016	Research fellow, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden Supervisor: Prof. Klas Blomgren

OTHER QUALIFICATIONS/ROLES/RESPONSIBILITIES

Year(s)	
2017	International Genetically Engineered Machine (iGEM) Team Leader of Bilkent University Bronze Medal
2016	International Genetically Engineered Machine (iGEM) Team Member of Bilkent University

	Silver Medal
2013-2017	Comprehensive scholarship holder, Bilkent University

SELECTED PUBLICATIONS

1. Seiboldt T, Zeiser C, Nguyen D, [Çelikyüreklı S](#), Herter S, Najafi S, Stroh-Dege A, Meulenbroeks C, Mack N, Salem-Altintas R, Westermann F, Schlesner M, Milde T, Kool M, Holland-Letz T, Vogler M, Peterziel H, Witt O, Oehme I. Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours. **Br J Cancer**. 2024 Sep;131(4):763-777. doi: 10.1038/s41416-024-02740-5. Epub 2024 Jun 28. PMID: 38942989.
2. Zhang Y, Mariz FC, Sehr P, Spagnoli G, Koenig KM, [Çelikyüreklı S](#), Kreuziger T, Zhao X, Bolchi A, Ottonello S, Müller M. Inter-epitope spacer variation within polytopic L2-based human papillomavirus antigens affects immunogenicity. **NPJ Vaccines**. 2024 Feb 24;9(1):44. doi: 10.1038/s41541-024-00832-0. PMID: 38402256.
3. Sigaud R, Rösch L, Gatzweiler C, Benzel J, von Soosten L, Peterziel H, Selt F, Najafi S, [Ayhan S](#), Gerloff XF, Hofmann N, Büdenbender I, Schmitt L, Foerster KI, Burhenne J, Haefeli WE, Korshunov A, Sahm F, van Tilburg CM, Jones DTW, Pfister SM, Knoerzer D, Kreider BL, Sauter M, Pajtler KW, Zuckermann M, Oehme I, Witt O, Milde T. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. **Neuro Oncol**. 2023 Mar 14;25(3):566-579. doi: 10.1093/neuonc/noac183. PMID: 35882450.
4. Gatzweiler C, Ridinger J, Herter S, Gerloff XF, ElHarouni D, Berker Y, Imle R, Schmitt L, Kreth S, Stainczyk S, [Ayhan S](#), Najafi S, Kronic D, Frese K, Meder B, Reuss D, Fiesel P, Schramm K, Blattner-Johnson M, Jones DTW, Banito A, Westermann F, Oppermann S, Milde T, Peterziel H, Witt O, Oehme I. Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models. **Cancers (Basel)**. 2022 Feb 8;14(3):849. doi: 10.3390/cancers14030849. PMID: 35159116.
5. Gatzweiler C, Ridinger J, [Ayhan S](#), Najafi S, Peterziel H, Witt O, Oehme I. Evaluation of Antitumor and On-Target Activity of HDAC Inhibitors with the Zebrafish Embryo Xenograft Model. **Methods Mol Biol**. 2023;2589:75-85. doi: 10.1007/978-1-0716-2788-4_5. PMID: 36255618.
6. Wrobel JK, Najafi S, [Ayhan S](#), Gatzweiler C, Kronic D, Ridinger J, Milde T, Westermann F, Peterziel H, Meder B, Distel M, Witt O, Oehme I. Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts. **Pharmaceuticals (Basel)**. 2020 Oct 27;13(11):345. doi: 10.3390/ph13110345. PMID: 33121173.